English
Spanishwelcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.
rareRelated
-
Immunotherapy for Graves’ OphthalmopathyPurpose of Review: In recent years, imm...
-
Surgical Treatment of Diplopia in Graves’ Orbitopathy PatientsPurpose: To review the authors' current...
-
Type 2 Diabetic Patients With Graves’ Disease Have More Frequent and Severe Graves’ OrbitopathyBackground and Aims: Due to the worldwi...
-
Michael K. Yoon, MDDr. Michael Yoon is a member of the Mass...
-
Hyperthyroid Patients Without Graves’ Orbitopathy are not at Increased Risk of Developing Glaucoma: A Nationwi...Purpose: Graves' disease (GD) and toxic...
-
Living Well With Thyroid Eye Disease – Webinarhttps://www.youtube.com/watch?v=45_mIC7b...
-
Eric Hink, MDEric Hink is Associate Professor of opht...
